Lexaria Bioscience Corp
LEXX0.583USD
-0.103-14.96%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
11.40MMarket Cap
LossP/E TTM
More Details of Lexaria Bioscience Corp Company
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Lexaria Bioscience Corp Info
Ticker SymbolLEXX
Company nameLexaria Bioscience Corp
IPO dateOct 28, 2009
CEOChristopher (Richard)
Number of employees7
Security typeOrdinary Share
Fiscal year-endOct 28
Address100 - 740 Mccurdy Road
CityKELOWNA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeV1X 2P7
Phone12507656424
Websitehttps://www.lexariabioscience.com/
Ticker SymbolLEXX
IPO dateOct 28, 2009
CEOChristopher (Richard)
Company Executives of Lexaria Bioscience Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Christopher A. (Chris) Bunka
Mr. Christopher A. (Chris) Bunka
Chairman of the Board
Chairman of the Board
655.46K
--
Mr. John Martin Docherty
Mr. John Martin Docherty
President, Director
President, Director
59.45K
--
Mr. William Edward (Ted) Mckechnie
Mr. William Edward (Ted) Mckechnie
Independent Director
Independent Director
18.19K
--
Mr. Nicholas W. (Nick) Baxter
Mr. Nicholas W. (Nick) Baxter
Independent Director
Independent Director
11.00K
--
Mr. Richard Christopher
Mr. Richard Christopher
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Albert (Al) Reese, Jr.
Mr. Albert (Al) Reese, Jr.
Independent Director
Independent Director
--
--
Mr. Michael (Mike) Shankman, CPA
Mr. Michael (Mike) Shankman, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Christopher A. (Chris) Bunka
Mr. Christopher A. (Chris) Bunka
Chairman of the Board
Chairman of the Board
655.46K
--
Mr. John Martin Docherty
Mr. John Martin Docherty
President, Director
President, Director
59.45K
--
Mr. William Edward (Ted) Mckechnie
Mr. William Edward (Ted) Mckechnie
Independent Director
Independent Director
18.19K
--
Mr. Nicholas W. (Nick) Baxter
Mr. Nicholas W. (Nick) Baxter
Independent Director
Independent Director
11.00K
--
Mr. Richard Christopher
Mr. Richard Christopher
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Albert (Al) Reese, Jr.
Mr. Albert (Al) Reese, Jr.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Dec 13
Updated: Sat, Dec 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bunka (Christopher A)
2.63%
Boos (Wayne W)
2.41%
Invenomic Capital Management LP
1.92%
Murchinson Ltd.
1.69%
The Vanguard Group, Inc.
1.04%
Other
90.31%
Shareholders
Shareholders
Proportion
Bunka (Christopher A)
2.63%
Boos (Wayne W)
2.41%
Invenomic Capital Management LP
1.92%
Murchinson Ltd.
1.69%
The Vanguard Group, Inc.
1.04%
Other
90.31%
Shareholder Types
Shareholders
Proportion
Individual Investor
6.12%
Investment Advisor/Hedge Fund
2.62%
Hedge Fund
1.97%
Investment Advisor
1.62%
Research Firm
0.68%
Other
86.98%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
46
2.42M
10.89%
+192.57K
2025Q2
55
2.62M
13.82%
-926.73K
2025Q1
58
2.67M
14.13%
-877.04K
2024Q4
57
2.74M
15.64%
-1.58M
2024Q3
53
2.33M
14.32%
-1.90M
2024Q2
51
3.71M
26.13%
+1.31M
2024Q1
48
2.53M
20.12%
-589.59K
2023Q4
42
2.77M
29.73%
-632.85K
2023Q3
39
3.31M
38.25%
+947.07K
2023Q2
37
2.00M
33.36%
-102.20K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bunka (Christopher A)
627.96K
2.83%
+100.00K
+18.94%
Jan 07, 2025
Boos (Wayne W)
600.00K
2.7%
-315.43K
-34.46%
Aug 31, 2024
Invenomic Capital Management LP
501.47K
2.26%
-48.48K
-8.82%
Jun 30, 2025
The Vanguard Group, Inc.
133.55K
0.6%
+5.68K
+4.44%
Jun 30, 2025
Geode Capital Management, L.L.C.
174.78K
0.79%
+2.32K
+1.35%
Jun 30, 2025
TD Securities, Inc.
133.13K
0.6%
+3.10K
+2.38%
Jun 30, 2025
Christopher (Richard C)
65.00K
0.29%
+15.00K
+30.00%
Jul 29, 2025
Docherty (John Martin)
59.45K
0.27%
+5.38K
+9.94%
Jul 29, 2025
State Street Investment Management (US)
39.30K
0.18%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Lexaria Bioscience Corp?
The top five shareholders of Lexaria Bioscience Corp are:
Bunka (Christopher A) holds 627.96K shares, accounting for 2.83% of the total shares.
Boos (Wayne W) holds 600.00K shares, accounting for 2.70% of the total shares.
Invenomic Capital Management LP holds 501.47K shares, accounting for 2.26% of the total shares.
The Vanguard Group, Inc. holds 133.55K shares, accounting for 0.60% of the total shares.
Geode Capital Management, L.L.C. holds 174.78K shares, accounting for 0.79% of the total shares.
Bunka (Christopher A) holds 627.96K shares, accounting for 2.83% of the total shares.
Boos (Wayne W) holds 600.00K shares, accounting for 2.70% of the total shares.
Invenomic Capital Management LP holds 501.47K shares, accounting for 2.26% of the total shares.
The Vanguard Group, Inc. holds 133.55K shares, accounting for 0.60% of the total shares.
Geode Capital Management, L.L.C. holds 174.78K shares, accounting for 0.79% of the total shares.
What are the top three shareholder types of Lexaria Bioscience Corp?
The top three shareholder types of Lexaria Bioscience Corp are:
Bunka (Christopher A)
Boos (Wayne W)
Invenomic Capital Management LP
Bunka (Christopher A)
Boos (Wayne W)
Invenomic Capital Management LP
How many institutions hold shares of Lexaria Bioscience Corp (LEXX)?
As of 2025Q3, 46 institutions hold shares of Lexaria Bioscience Corp, with a combined market value of approximately 2.42M, accounting for 10.89% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -2.93%.
What is the biggest source of revenue for Lexaria Bioscience Corp?
In --, the -- business generated the highest revenue for Lexaria Bioscience Corp, amounting to -- and accounting for --% of total revenue.
